A phase II study by the Groupe Francophone des Myélodysplasies (GFM) tested eprenetapopt in combination with azacitidine in untreated high- or very-high-risk TP53-mutated MDS (34) and AML (18) patients. Here, TP53 is linked to myelodysplastic syndrome.